Srs Capital Advisors, Inc. Black Diamond Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $8.6 Billion
- Q3 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 66 shares of BDTX stock, worth $277. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66Holding current value
$277% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
97Shares Held
41.5MCall Options Held
68.7KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$45.2 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.55MShares$23.4 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$18.7 Million1.03% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$13.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$9.22 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $153M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...